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The technique of PCR for detection of
Aspergillus in human specimens has been
around in one form or another for almost
2 decades [1], but it is still regarded as too
experimental to use for defining invasive
fungal disease [2]. The reasons for not in-
cluding PCR in the European Organisa-
tion for Research on Treatment of Cancer
and the Mycoses Study Group criteria are
as frustrating as they are manifold but in-
clude the lack of standardization and the
absence of a commercially available system
[3]. Notwithstanding the slow develop-
ment, there have been advances, as at-
tested by the study by White and col-
leagues in this issue of the journal [4]. This
group is based in Cardiff, United King-
dom, and has employed a modified PCR
method from a previous coworker [5] for
use in a clinical setting. Their primary aim
was to assess the performance of PCR in
terms of diagnosing invasive aspergillosis,
and they succeeded in supporting the
value of a negative PCR result for ruling
out IA, thereby helping to limit empirical
therapy to those patients who are most
likely to have the disease.
The authors went to a great deal of trou-
ble to undertake the study. They took the
British Society for Medical Mycology’s
proposed standards of care for patients
with invasive fungal infections as their
starting point [6] but did not seem to
manage to enlist the full cooperation of
their hematology colleagues. High-reso-
lution CT scans were recommended for
all patients with suspected IA, but the
compliance of the clinicians was only 37%.
Although no one expects 100% compli-
ance for this patient population, others
have shown that this type of imaging is
attainable in the majority of cases [7, 8].
Compliance in submitting blood samples
for the galactomannan ELISA test twice
weekly was also low, ∼50%. This makes
estimating the true incidence of IA in this
population unreliable and may have led
to underdiagnosis of IA.
The authors also made every effort to
minimize variation in the performance of
PCR by choosing whole blood samples,
rather than plasma or serum samples, and
employing a modified version of the ex-
traction method used by a Tu¨bingen
group [9] and the standardized Light Cy-
cler (Roche) method for real-time PCR.
In this way, they had an assay capable of
reliably detecting the equivalent of 5 cfu
of Aspergillus, which is in the same range
as found in experimentally infected mice
[10]. It is true that they used Aspergillus
primers that were different from those em-
ployed by others [11–19], choosing in-
stead ones that performed well in a pre-
vious study [5]. Nonetheless, their assay
was sensitive by any standards, so that a
negative result effectively meant the ab-
sence of fungal DNA, even though the
converse was not the case.
The authors succeeded in showing a
clear relationship between positivity rates
for PCR and those for patients but not
those for samples. Of the 13 patients with
proven or probable IA, 12 (92%) had serial
positive PCR results, whereas this was the
case for only 6 (15%) of the 40 patients
with possible IA and 8 (5%) of the 149
patients at risk who had no evidence of
IA. The negative predictive value was 99%,
with corresponding sensitivity of 92% and
specificity of 95%. The performance of
their PCR also compares favorably with
that of previous studies, yielding high like-
lihood ratios of probable/proven IA for a
positive test result (table 1).
Therefore, it is fair to conclude, as the
authors did, that failure to detect Asper-
gillus by PCR in blood specimens obtained
twice weekly should allow a wait-and-see
approach to be taken, thereby reducing the
need for empirical antifungal therapy by
∼50%. This is in line with the recent re-
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Table 1. Comparison of different studies of PCR for invasive aspergillosis (IA).
Reference
No. of
patients
(episodes)
in study
No. (%) of
patients with
probable/
proven IA
PCR
sensitivity,
%
PCR
specificity,
%
Likelihood ratio of
probable/proven IA
Positive PCR
test result
Negative PCR
test result
[13] 86 21 (24) 100 98 50.00 !0.01
[20] 93 22 (24) 100 89 9.09 !0.01
[14] 84 7 (8) 100 65 2.86 !0.01
[15] 92 14 (15) 100 73 3.70 !0.01
[5] 37 13 (35) 81 100 1100 0.19
[19] 121 3 (2) 75 96 18.75 0.26
[11] 218 33 (15) 2 81.3 4.90 0.10
[17] 122 33 (27) 79 92 9.88 0.23
[12] 165 (205) 11 (7) 64 63.5 1.74 0.57
[18] 96 (149) 11 (11) 64 87 4.92 0.41
[16] 78 (175) 8 (10) 75 70 2.50 0.36
[4] 202 13 (6) 92 95 17.09 0.08
sults of a study from Leuven, Belgium, by
Maertens et al. [21], who found that de-
tection of galactomannan 3 times weekly
in serum drawn on a daily basis could
reduce the need for empirical therapy by
at least 78%.
What other conclusions can be drawn?
It is striking that, as with the development
of galactomannan, the progress toward us-
ing PCR seems, with the notable exception
of a Tokyo group [17, 18], to be a pri-
marily European affair involving a few
centers. The researchers who opt to study
PCR for screening high-risk patients seem
to be not particularly enamored of gal-
actomannan testing, and vice versa. This
is a pity because combining these 2 tests,
perhaps also with b-d-glucan testing,
might, in fact, offer a better means of in-
cluding or excluding the diagnosis of IA,
because each measures different compo-
nents of fungi. However, it may not be
that simple, because Kami et al. [17]
showed that PCR detected the presence of
Aspergillus earlier than did either galac-
tomannan ELISA or the b-d-glucan test,
and, in a later study, the same group found
that combining the tests reduced sensitiv-
ity [18]. A smaller study [22] indicated
why this might be, showing (using a var-
iant of the method of Einsele et al. [13])
that PCR was more sensitive than the gal-
actomannan ELISA, whereas the latter test
was more specific. The apparent discrep-
ancies are likely to be partly the result of
widely differing frequencies of probable
and proven IA in the different popula-
tions, because the actual performance of
any test is dependent on the a priori prob-
ability—that is, the prevalence. As shown
in table 1, the frequency of probable/
proven IA varied markedly for tests with
a high specificity, for which a positive re-
sult suggests a diagnosis of IA, which was
also reflected in the likelihood ratios. Sim-
ilar variation was seen for tests with a high
sensitivity, for which a negative result rules
out the diagnosis of IA. This makes it dif-
ficult for others to adopt PCR for
screening.
Clearly, only a prospective, multicenter
study of sufficient size can provide an an-
swer to the question of whether screening
would help direct therapy to patients that
need it while exempting those that do not.
The study of White et al. [4] gives grounds
for optimism while clearly highlighting the
need for minimum standards of diagnosis
in any undertaking. Their expertise to-
gether with that of others in the field pro-
vides enough critical mass to help generate
a common PCR protocol. Centers, in-
cluding my own, that have opted for gal-
actomannan ELISA will be more keen to
join forces to form a multicenter base that
would be sufficiently large to allow re-
cruitment, within a reasonable time, of the
necessarily large number of patients at
risk. The costs incurred could be defrayed
by the savings on expensive antifungal
agents, some of which cost several hun-
dred euros a day.
It would be ideal if funding from grant
agencies could be found, but this is un-
likely in the current climate of budget re-
strictions, because IA fails the test of high
societal impact. On the other hand, it
would be wrong to expect commercial en-
terprises to entirely foot the bill for this
undertaking. The problem is clearly the
province of health care providers. The im-
petus provided by White et al. [4] should
encourage all parties to combine their ef-
forts and establish a sort of consortium to
support a study that is clearly needed to
obtain evidence on which clinicians can
base their decisions now and in the future.
Let us hope we will not have to wait an-
other decade.
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